Atomoxetine treatment may decrease striatal dopaminergic transporter availability after 8 weeks: pilot SPECT report of three cases

Creative Commons License

AKAY A., ÇAPA KAYA G., BAYKARA H. B., Demir Y., Oezek H., ALŞEN GÜNEY S., ...More

NEUROPSYCHIATRIC DISEASE AND TREATMENT, vol.11, pp.2909-2911, 2015 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 11
  • Publication Date: 2015
  • Doi Number: 10.2147/ndt.s87359
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.2909-2911
  • Keywords: neuroimaging, dopamine, noradrenaline, SLC6A3 protein, human, pragmatic clinical trial, pilot study, DEFICIT HYPERACTIVITY DISORDER, METHYLPHENIDATE TREATMENT, GENETICS, ADHD
  • Dokuz Eylül University Affiliated: Yes


Attention deficit/hyperactivity disorder is one of the most common neurodevelopmental disorders. The pathophysiology is thought to involve noradrenaline and dopamine. The role of dopamine transporter (DAT) was evaluated in imaging studies using mostly dopamine reuptake inhibitors. Atomoxetine is a selective noradrenaline reuptake inhibitor. Here we report the results of a pilot study conducted to evaluate changes in striatal DAT after 8 weeks of atomoxetine treatment. Our results suggest that 8 weeks of atomoxetine treatment may change striatal DAT bioavailability as measured via SPECT but that change was not correlated with genotype or clinical improvement.